Effectiveness of Nirsevimab Immunoprophylaxis Against Respiratory Syncytial Virus-Related Outcomes in Hospital and Primary Care Settings: A Retrospective Cohort Study in Infants in Catalonia (Spain)
- Ermengol Coma; Montserrat Martinez-Marcos; Eduardo Hermosilla; Jacobo Mendioroz; Anna Reñé; Francesc Fina
Access Resources
About
This study in Catalonia, Spain looks at the effectiveness of nirsevimab, a monoclonal antibody for RSV, in infants under 6 months old. The study shows significant reductions in hospital and ICU admissions for RSV-related conditions after nirsevimab administration. The research also shows fewer cases of RSV infections and related illnesses like pneumonia and bronchiolitis treated in primary care settings. These findings help guide public health decisions on using nirsevimab for preventing severe RSV outcomes in young children during their first epidemic season.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.